|
🐜
|
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
24 auth.
T. Choueiri,
B. Escudier,
T. Powles,
P. Mainwaring,
B. Rini,
F. Donskov,
H. Hammers,
Thomas E. Hutson,
Jae-Lyun Lee,
K. Peltola,
...
B. Roth,
G. Bjarnason,
L. Géczi,
B. Keam,
P. Maroto,
D. Heng,
M. Schmidinger,
P. Kantoff,
A. Borgman-Hagey,
C. Hessel,
C. Scheffold,
G. Schwab,
N. Tannir,
R. Motzer
|
10 |
2015 |
10
🐜
|
|
🐜
|
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
22 auth.
L. Chow,
R. Haddad,
Shilpa Gupta,
A. Mahipal,
R. Mehra,
M. Tahara,
R. Berger,
J. Eder,
B. Burtness,
Se-Hoon Lee,
...
B. Keam,
Hyunseok Kang,
K. Muro,
J. Weiss,
R. Geva,
Chia‐Chi Lin,
H. Chung,
Amy Meister,
M. Dolled-Filhart,
K. Pathiraja,
Jonathan D. Cheng,
T. Seiwert
|
9 |
2016 |
9
🐜
|
|
🐜
|
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
20 auth.
R. Mehra,
T. Seiwert,
Shilpa Gupta,
J. Weiss,
I. Gluck,
J. Eder,
B. Burtness,
M. Tahara,
B. Keam,
Hyunseok Kang,
...
K. Muro,
R. Geva,
H. Chung,
Chia‐Chi Lin,
D. Aurora-Garg,
A. Ray,
K. Pathiraja,
Jonathan C Cheng,
L. Chow,
R. Haddad
|
8 |
2018 |
8
🐜
|
|
🐜
|
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
23 auth.
J. Lee,
J. Lee,
Sehui Kim,
Soyeon Kim,
J. Youk,
Seongyeol Park,
Yohan An,
B. Keam,
Dong-Wan Kim,
D. Heo,
...
Y. T. Kim,
Jin-Soo Kim,
Se Hyun Kim,
J. Lee,
Se-Hoon Lee,
Keunchil Park,
J. Ku,
Y. Jeon,
D. Chung,
P. Park,
J. Kim,
T. Kim,
Y. Ju
|
8 |
2017 |
8
🐜
|
|
🐜
|
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
14 auth.
A. Hansen,
C. Massard,
P. Ott,
N. Haas,
Juanita Lopez,
S. Ejadi,
J. Wallmark,
B. Keam,
J. Delord,
R. Aggarwal,
...
M. Gould,
Ping Yang,
S. Keefe,
S. Piha-Paul
|
8 |
2018 |
8
🐜
|
|
🐜
|
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
22 auth.
R. Ferris,
R. Haddad,
C. Even,
M. Tahara,
M. Dvorkin,
T. Ciuleanu,
P. Clement,
R. Mesía,
S. Kutukova,
L. Zholudeva,
...
A. Daste,
J. Caballero-Daroqui,
B. Keam,
I. Vynnychenko,
C. Lafond,
J. Shetty,
H. Mann,
J. Fan,
S. Wildsmith,
N. Morsli,
J. Fayette,
L. Licitra
|
8 |
2020 |
8
🐜
|
|
🦁
|
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
14 auth.
B. Keam,
S. Im,
Kyung-Hun Lee,
Sae-Won Han,
D. Oh,
J. Kim,
Se-Hoon Lee,
W. Han,
Dong-Wan Kim,
Tae-You Kim,
...
I. Park,
D. Noh,
D. Heo,
Y. Bang
|
7 |
2011 |
7
🦁
|
|
🐜
|
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
10 auth.
C. Ock,
B. Keam,
Sehui Kim,
Ju-Seog Lee,
Miso Kim,
T. Kim,
...
Y. Jeon,
Dong-Wan Kim,
D. Chung,
D. Heo
|
7 |
2016 |
7
🐜
|
|
🐜
|
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
35 auth.
S. Pal,
J. Rosenberg,
J. Hoffman-Censits,
R. Berger,
D. Quinn,
M. Galsky,
J. Wolf,
C. Dittrich,
B. Keam,
J. Delord,
J. Schellens,
G. Gravis,
J. Medioni,
P. Maroto,
V. Sriuranpong,
...
C. Charoentum,
H. Burris,
V. Grünwald,
D. Petrylak,
U. Vaishampayan,
E. Gez,
U. de Giorgi,
Jae-Lyun Lee,
J. Voortman,
Sumati V Gupta,
Sunil Sharma,
A. Mortazavi,
D. Vaughn,
R. Isaacs,
K. Parker,
Xueying Chen,
Kun Yu,
D. Porter,
Diana Graus Porta,
D. Bajorin
|
7 |
2018 |
7
🐜
|
|
🐜
|
Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor
10 auth.
T. Kim,
Ahnah Song,
Dong-Wan Kim,
Soyeon Kim,
Y. Ahn,
B. Keam,
...
Y. Jeon,
Se-Hoon Lee,
D. Chung,
D. Heo
|
7 |
2015 |
7
🐜
|
|
🐜
|
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
13 auth.
Se-Hoon Lee,
J. Lee,
M. Ahn,
D-W. Kim,
Jong-Mu Sun,
B. Keam,
Tae Min Kim,
D. Heo,
J. Ahn,
Yoon-La Choi,
...
H. Min,
Y. Jeon,
Keunchil Park
|
7 |
2016 |
7
🐜
|
|
🐜
|
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
25 auth.
V. Subbiah,
Mimi I Hu,
L. Wirth,
M. Schuler,
A. Mansfield,
G. Curigliano,
M. Brose,
V. Zhu,
S. Leboulleux,
D. Bowles,
C. Baik,
D. Adkins,
B. Keam,
I. Matos,
E. Garralda,
...
J. Gainor,
G. Lopes,
Chia‐Chi Lin,
Y. Godbert,
D. Sarker,
Stephen G. Miller,
C. Clifford,
Hui Zhang,
C. Turner,
Matthew H. Taylor
|
7 |
2021 |
7
🐜
|
